2013•PubMedRequires access
[Successful treatment with rituximab in a patient with refractory mixed-type autoimmune hemolytic anemia].
Kaoru Ono, Tsutomu Sato, Satoshi Iyama, Ayumi Tatekoshi, Akari Hashimoto, Yusuke Kamihara, Hiroto Horiguchi, Shohei Kikuchi, Kohichi Takada, Tsuyoshi Hayashi, Koji Miyanishi, Yasushi Sato, Rishu Takimoto, Masayoshi Kobune, Junji Kato
Open publisher page 0 citations
Abstract
The evidence that rituximab is effective therapy for refractory warm or cold autoimmune hemolytic anemia (AIHA) has been accumulating; however, the efficacy of rituximab for mixed-type AIHA is not evident. Herein, we report a case of mixed-type AIHA refractory to corticosteroids and splenectomy, but successfully treated with rituximab (375 mg/m(2)/day, once weekly, four times). She achieved a complete response, which has been maintained for 16 months, to date, despite steroid tapering. Our case suggests that rituximab therapy should be considered for refractory AIHA even of mixed-type.